Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
Vivo Opportunity funds reported significant stakes in InMed Pharmaceuticals Inc. and outlined their role in a pending merger. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC beneficially own 718,444 common shares, or 21.7% of InMed’s 3,314,063 shares outstanding as of May 4, 2026. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC beneficially own 72,535 common shares, or 2.2% of the class.
The filing explains that on May 19, 2026, InMed agreed to acquire Mentari Therapeutics, Inc. through a two-step merger, with Mentari becoming an indirect wholly owned subsidiary. Certain investors, including the Vivo funds, also agreed to a pre-closing financing in which they will buy Mentari stock that will convert into InMed common shares at the same exchange ratio used in the merger. The Vivo funds state they acquired InMed shares in open-market purchases beginning May 19, 2026 and ending June 8, 2026, and that they hold the shares for investment purposes.
InMed Pharmaceuticals Inc. reported significant insider buying by entities associated with Vivo Opportunity. Over multiple open-market purchases from May 20 to June 8, 2026, Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. acquired a combined 249,227 common shares at prices generally between $1.42 and $1.75 per share. The funds’ general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, are listed as reporting persons but each disclaims beneficial ownership beyond its pecuniary interest.
InMed Pharmaceuticals Inc. reported initial insider holdings for several Vivo Opportunity investment entities. Vivo Opportunity Cayman Fund, L.P. indirectly holds 49,679 common shares, while Vivo Opportunity Fund Holdings, L.P. indirectly holds 492,073 common shares. The general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, each disclaim beneficial ownership except to the extent of their pecuniary interest.
InMed Pharmaceuticals Inc. has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed that the company’s common shares closed at or above $1.00 per share for 10 consecutive business days from May 19, 2026 through June 2, 2026.
This closes a prior deficiency notice InMed received in March 2026 after its shares traded below $1.00 for 30 consecutive business days. The company remains listed on Nasdaq and has disclosed the update via an 8-K and accompanying press release.
InMed Pharmaceuticals reports beneficial ownership disclosure by ADAR1 Capital Management and Daniel Schneeberger. The filing states 800,000 shares of Common Shares are beneficially owned by private funds managed by ADAR1 Capital Management, representing 24.1% of Common Shares based on May 4, 2026 outstanding shares of 3,314,063. The filing notes these shares are held directly by ADAR1-managed funds and may be indirectly beneficially owned by Daniel Schneeberger as sole manager.
InMed Pharmaceuticals Inc. ownership disclosure: Squadron Master Fund LP and related reporting persons report beneficial ownership of 325,000 shares of common stock, representing 9.8% of the class. The filing states 3,314,063 shares outstanding as of May 4, 2026.
The statement lists shared voting and dispositive power over the 325,000 shares for Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank. The filing includes an express disclaimer of beneficial ownership by Squadron Capital Management LLC and the named partners pursuant to Rule 13d-4.
Private investment funds managed by ADAR1 Capital Management, LLC bought 468,551 InMed Pharmaceuticals common shares in open-market transactions on May 19, 2026. Individual trades included 200,000 shares at $1.4990, 200,000 shares at $1.5604, and 68,551 shares at $1.5998, all reported as indirect ownership. Footnotes state the securities are owned directly by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, who each disclaim beneficial ownership beyond their pecuniary interest.
InMed Pharmaceuticals Inc. filed an initial ownership report showing that private investment funds managed by ADAR1 Capital Management, LLC hold 331,449 Common Shares of InMed. These shares may be deemed indirectly beneficially owned by ADAR1 and by Daniel Schneeberger, its sole manager, through their interests in the funds.
Both ADAR1 and Schneeberger are listed as ten percent owners. The filing states that each reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.
The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.
InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.
The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.
InMed Pharmaceuticals Inc. entered into an Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. to combine the companies through a two-step merger structure, subject to customary closing conditions and shareholder approvals. The Exchange Ratio is based on a contemplated Mentari equity value of $125,000,000 and related financing.
The parties expect, on a pro forma basis, pre-Merger Mentari stockholders to own approximately 98.49% and pre-Merger InMed shareholders approximately 1.51% of the combined company. Closing requires receipt of not less than $150,000,000 in Mentari's pre-closing financing, Nasdaq listing approval, the Form S-4 becoming effective, and shareholder approvals. The transaction contemplates issuance of non-voting Convertible Preferred Shares convertible into 1,000 Common Shares each and includes a Contingent Value Rights plan for pre-Merger InMed shareholders.
InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.
Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.
InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.
Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.
InMed Pharmaceuticals agreed to merge with privately held Mentari Therapeutics in an all‑stock transaction that will effectively hand control to Mentari and refocus the business on migraine prevention therapies. The deal uses a two‑step merger structure in which Mentari becomes a wholly owned subsidiary and InMed creates non‑voting convertible preferred shares to support the new ownership and governance framework.
Based on the exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.49% of the combined company and pre‑merger InMed shareholders about 1.51%, with Mentari designating post‑closing directors and officers. Closing is conditioned on shareholder and regulatory approvals, Nasdaq listing clearance and a pre‑closing Mentari financing of at least $150 million. In parallel, an oversubscribed private placement of roughly $290 million is expected to fund operations through 2028, supporting Mentari’s MT‑001 and MT‑002 migraine pipelines. Pre‑merger InMed holders will receive contingent value rights tied to any future monetization of InMed’s legacy assets.